AI in drug discovery Position Precision Therapeutics as a data and AI driven biotech partner with ongoing AI infrastructure initiatives and strategic compute reserves. Leverage their recent ATH DAT and Aethir DAT launches as indicators of commitment to scalable, cost-efficient AI resources that can complement external collaborations on AI-driven drug discovery and predictive modeling.

Clinical and research labs Highlight their CLIA-certified clinical laboratory alongside a state-of-the-art oncology research facility in Pittsburgh. Propose value through integrated services spanning translational research, biomarker development, and clinically actionable assays to accelerate bench-to-bedside workflows for pharmaceutical and biotech clients.

Growth through partnerships Emphasize opportunities around joint research programs and collaborations with biopharma, CROs, and diagnostics companies given their active engagement in SLAS related activities and partnerships with industry players like Tecan. Offer pilot collaborations for assay validation, 3D cell culture models, or tumor profiling projects.

Growth and financials Note the modest revenue scale relative to peers and 51-200 employees, indicating a potential target for mid-market solutions that can scale with them. Propose scalable software, data analytics platforms, cloud-based compute, and automation tools to support expanding lab operations and data processing needs.

Market position Position as a niche AI-driven oncology firm with a suite that includes ChemoFx and 3D cell culture models. Deliver value to customers seeking precision oncology solutions, tumor profiling, and predictive models, while offering integration with existing diagnostic workflows and potential international expansion through the planned European launch.